Breast Cancer Clinical Trial

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Summary

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent.
Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 (HER-2) and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.

Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC:

Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab)
Anti-EGFR monoclonal antibody (cetuximab or panitumumab)
BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations
Expansion Cohort I (UC, Maintenance Therapy): Subjects with histologically confirmed, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who received first-line chemotherapy of gemcitabine + cisplatin and/or gemcitabine + carboplatin.
Expansion Cohort J (UC, ICI-refractory): Subjects with histologically confirmed, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who progressed on or after PD-1/PD-L1 targeting ICI therapy.
Expansion Cohort K (UC, platinum-refractory): Subjects with histologically confirmed, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who progressed on or after first-line platinum-based combination therapy.
Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1, with exception of Cohort I (UC, Maintenance Therapy).

Tumor tissue material:

Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.
Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
Adequate organ and marrow function.
Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.
Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, H, I, and K only), prior treatment with avelumab (Cohort J only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only).
Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.
Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment.
Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
Uncontrolled, significant intercurrent or recent illness.
Concomitant use of certain medications.
Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males and > 470 ms for females. Single ECGs are no longer permitted.
Pregnant or lactating females.
Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.

Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:

Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.

Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:

Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1195

Study ID:

NCT03845166

Recruitment Status:

Recruiting

Sponsor:

Exelixis

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 70 Locations for this study

See Locations Near You

Exelixis Clinical Site #6
Duarte California, 91010, United States
Exelixis Clinical Site #49
La Jolla California, 92093, United States
Exelixis Clinical Site #7
Los Angeles California, 90025, United States
Exelixis Clinical Site #66
San Francisco California, 94158, United States
Exelixis Clinical Site #15
Lake Mary Florida, 32746, United States
Exelixis Clinical Site #24
Miami Florida, 33136, United States
Exelixis Clinical Site #11
Atlanta Georgia, 30341, United States
Exelixis Clinical Site #41
Iowa City Iowa, 52242, United States
Exelixis Clinical Site #36
Westwood Kansas, 66205, United States
Exelixis Clinical Site #62
Scarborough Maine, 04074, United States
Exelixis Clinical Site #44
Baltimore Maryland, 21201, United States
Exelixis Clinical Site #4
Boston Massachusetts, 02215, United States
Exelixis Clinical Site #45
Ann Arbor Michigan, 48109, United States
Exelixis Clinical Site #2
Grand Rapids Michigan, 49546, United States
Exelixis Clinical Site #25
Saint Paul Minnesota, 55101, United States
Exelixis Clinical Site #13
Omaha Nebraska, 68130, United States
Exelixis Clinical Site #9
East Brunswick New Jersey, 08816, United States
Exelixis Clinical Site #35
New York New York, 10029, United States
Exelixis Clinical Site #60
Cleveland Ohio, 44106, United States
Exelixis Clinical Site #59
Hershey Pennsylvania, 17033, United States
Exelixis Clinical Site #58
Philadelphia Pennsylvania, 19107, United States
Exelixis Clinical Site #12
Pittsburgh Pennsylvania, 15232, United States
Exelixis Clinical Site #61
Charleston South Carolina, 29425, United States
Exelixis Clinical Site #50
Myrtle Beach South Carolina, 29572, United States
Exelixis Clinical Site #33
Germantown Tennessee, 38138, United States
Exelixis Clinical Site #3
Houston Texas, 77030, United States
Exelixis Clinical Site #1
San Antonio Texas, 78229, United States
Exelixis Clinical Site #5
Salt Lake City Utah, 84112, United States
Exelixis Clinical Site #8
Charlottesville Virginia, 22903, United States
Exelixis Clinical Site #43
Richmond Virginia, 23219, United States
Exelixis Clinical Site #26
Spokane Washington, 99208, United States
Exelixis Clinical Site #52
Darlinghurst New South Wales, 2010, Australia
Exelixis Clinical Site #53
Liverpool New South Wales, 2170, Australia
Exelixis Clinical Site #56
Kurralta Park South Australia, 5037, Australia
Exelixis Clinical Site #63
Heidelberg Victoria, 3084, Australia
Exelixis Clinical Site #44
Edegem Antwerpen, 2650, Belgium
Exelixis Clinical Site #51
Bruxelles Brussels, 1200, Belgium
Exelixis Clinical Site #65
Gent Oost-Vlaanderen, 9000, Belgium
Exelixis Clinical Site #21
Brno , 656 9, Czechia
Exelixis Clinical Site #42
Hradec Králové , 500 0, Czechia
Exelixis Clinical Site #10
Olomouc , 779 0, Czechia
Exelixis Clinical Site #27
Praha , 140 5, Czechia
Exelixis Clinical Site #46
Clermont Ferrand, 63011, France
Exelixis Clinical Site #37
Saint-Herblain Cedex Loire Atlantique, 44805, France
Exelixis Clinical Site #32
Caen Cedex 5 , 14076, France
Exelixis Clinical Site #48
Marseille , 13009, France
Exelixis Clinical Site #14
Paris , 75015, France
Exelixis Clinical Site #39
Pierre-Bénite , 69310, France
Exelixis Clinical Site #47
Poitiers , 86000, France
Exelixis Clinical Site #22
Suresnes , 92150, France
Exelixis Clinical Site #57
Toulouse Cedex 9 , 31059, France
Exelixis Clinical Site #38
Nürtingen Baden-Wuerttemberg, 72622, Germany
Exelixis Clinical Site #28
München Bavaria, 81675, Germany
Exelixis Clinical Site #31
Münster North Rhine-Westphalia, 48149, Germany
Exelixis Clinical Site #64
Hamburg , 20249, Germany
Exelixis Clinical Site #67
Milano MI, 20132, Italy
Exelixis Clinical Site #69
Pavia PV, 27100, Italy
Exelixis Clinical Site #54
Milan , 20141, Italy
Exelixis Clinical Site #23
Sabadell Barcelona, 08208, Spain
Exelixis Clinical Site #20
Santiago De Compostela La Coruna, 15706, Spain
Exelixis Clinical Site #18
Barcelona , 08003, Spain
Exelixis Clinical Site #19
Barcelona , 08023, Spain
Exelixis Clinical Site #29
Barcelona , 08035, Spain
Exelixis Clinical Site #30
Barcelona , 08036, Spain
Exelixis Clinical Site #34
Madrid , 28040, Spain
Exelixis Clinical Site #55
Madrid , 28041, Spain
Exelixis Clinical Site #17
Madrid , 28046, Spain
Exelixis Clinical Site #16
Sevilla , 41013, Spain
Exelixis Clinical Site #40
Sutton England, SM2 5, United Kingdom
Exelixis Clinical Site #68
Preston Lancashire, PR29H, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

1195

Study ID:

NCT03845166

Recruitment Status:

Recruiting

Sponsor:


Exelixis

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.